|Articles|April 1, 1999

April 1999
Volume 5
Issue 4

Targeted Intervention Programs: Creating a Customized Practice Model to Improve the Treatment of Allergic Rhinitis in a Managed Care Population

Author(s)Cindy Gregory, PhD, Mary Cifaldi, RPh, MSHA, L. Ann Tanner, RPh, MPH

Download PDF: Targeted Intervention Programs: Creating a Customized Practice Model to Improve the Treatment of Allergic Rhinitis in a Managed Care Population

Articles in this issue

over 27 years ago

Article

Medicaid Recipients' Experiences Under Mandatory Managed Care

over 27 years ago

Article

Why Primary Care Physicians Join HMOs

over 27 years ago

Article

Discontinuation Rates of Cholesterol-Lowering Medications

over 27 years ago

Article

The Role of Resource Allocation Models in Selecting Clinical Preventive Services

over 27 years ago

Article

Is Prior Authorization of Topical Tretinoin for Acne Cost Effective?

over 27 years ago

Article

Impact of Therapeutic Interchange from Pravastatin to Lovastatin in a Veterans Affairs Medical Center

over 27 years ago

Article

Disease Management of Congestive Heart Failure

over 27 years ago

Article

Celecoxib: A COX-2 Inhibitor

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Targeted Intervention Programs: Creating a Customized Practice Model to Improve the Treatment of Allergic Rhinitis in a Managed Care Population

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs

Innovation Is Outpacing Reimbursement, Health System Execs Warn

MS Likely Unfolds Along a Continuum Years Before First Symptoms